- Home
- XERS vs ACNB Comparison
XERS vs ACNB Comparison
Compare XERS & ACNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- ACNB
- Stock Information
- Founded
- XERS 2005
- ACNB 1857
- Country
- XERS United States
- ACNB United States
- Employees
- XERS N/A
- ACNB N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- ACNB Major Banks
- Sector
- XERS Health Care
- ACNB Finance
- Exchange
- XERS Nasdaq
- ACNB Nasdaq
- Market Cap
- XERS 526.3M
- ACNB 433.8M
- IPO Year
- XERS 2018
- ACNB N/A
- Fundamental
- Price
- XERS $4.24
- ACNB $41.31
- Analyst Decision
- XERS Strong Buy
- ACNB Strong Buy
- Analyst Count
- XERS 4
- ACNB 3
- Target Price
- XERS $5.75
- ACNB $51.50
- AVG Volume (30 Days)
- XERS 2.4M
- ACNB 38.4K
- Earning Date
- XERS 03-06-2025
- ACNB 04-24-2025
- Dividend Yield
- XERS N/A
- ACNB 3.10%
- EPS Growth
- XERS N/A
- ACNB 0.54
- EPS
- XERS N/A
- ACNB 3.73
- Revenue
- XERS $203,070,000.00
- ACNB $111,104,000.00
- Revenue This Year
- XERS $20.47
- ACNB $35.59
- Revenue Next Year
- XERS $19.35
- ACNB $9.07
- P/E Ratio
- XERS N/A
- ACNB $11.08
- Revenue Growth
- XERS 23.89
- ACNB 4.89
- 52 Week Low
- XERS $1.69
- ACNB $30.24
- 52 Week High
- XERS $4.50
- ACNB $50.72
- Technical
- Relative Strength Index (RSI)
- XERS 70.54
- ACNB 51.71
- Support Level
- XERS $3.59
- ACNB $40.35
- Resistance Level
- XERS $4.50
- ACNB $44.42
- Average True Range (ATR)
- XERS 0.25
- ACNB 1.30
- MACD
- XERS 0.03
- ACNB 0.03
- Stochastic Oscillator
- XERS 72.34
- ACNB 36.83
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Bank which generates the majority of the revenue provides banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.